Breaking News: VolitionRX Sets Record with $1.9 Million Registered Direct Offering!
Description:
Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition” or the “Company”), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i) 445,648 shares of its common stock to certain directors and executive officers of the Company (the “Insiders”) at an offering price of $0.5722 per share, and (ii) 2,857,389 shares of its common stock, together with common stock purchase warrants, composed of Form A warrants to purchase up to 2,857,389 shares of common stock and Form B warrants to purchase up to 1,428,693 shares of common stock (collectively, the “Warrants”), to other investors at a combined offering price of $0.5722 per share and accompanying warrants. The Form A warrants and Form B warrants have an exercise price per share of $0.5722 and $0.71525, respectively, are exercisable immediately, and expire five years from the issuance date.
How will this affect me?
As an individual investor, this news could affect you depending on your involvement with VolitionRx Limited. If you are a shareholder, this direct offering may impact the value of your shares in the company. It is essential to stay informed about these financial developments to make informed decisions regarding your investment portfolio.
How will this affect the world?
For the world at large, this record-setting direct offering by VolitionRx Limited signals potential growth and expansion within the field of epigenetics. The additional funds raised through this offering could potentially lead to advancements in research and technology that could have far-reaching implications in the world of healthcare and biotechnology.
Conclusion:
In conclusion, VolitionRx Limited’s $1.9 million registered direct offering marks a significant milestone for the company and the field of epigenetics. This financial development has the potential to impact investors and the broader world through advancements in research and technology. It will be interesting to see how this offering propels VolitionRx Limited forward in the coming years.
